Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis.

@article{Bendele2000CombinationBO,
  title={Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis.},
  author={Alison M. Bendele and Elizabeth S Chlipala and Jon Scherrer and Joshua Frazier and Gina Sennello and William J Rich and Carl Keith Edwards},
  journal={Arthritis and rheumatism},
  year={2000},
  volume={43 12},
  pages={2648-59}
}
OBJECTIVE To determine the potential for additive or synergistic effects of combination therapy with the recombinant anticytokine agents interleukin-1 receptor antagonist (IL-1Ra) and PEGylated soluble tumor necrosis factor receptor type I (PEG sTNFRI) in established type H collagen-induced arthritis (CIA) and developing adjuvant-induced arthritis (AIA) in rats. METHODS Rats with established CIA or developing AIA were treated with various doses of IL-1Ra in a slow-release hyaluronic acid… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 53 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 55 references

A phase 1 study of PEGylated soluble tumor necrosis factor receptor type I ( PEG sTNFRI [ p 55 ] ) in subjects with rheumatoid arthritis [ abstract ]

  • Caldwell, MW Davis, K Jelaca-Maxwell, A Wang, S Wason, W Chase
  • Arthritis Rheum
  • 1999

A phase 1 study of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI [p55]) in subjects with rheumatoid arthritis

  • JR Caldwell, MW Davis, K Jelaca-Maxwell, A Wang, S Wason, W Chase
  • [abstract]. Arthritis Rheum
  • 1999
1 Excerpt

Blocking IL-1 and TNF

  • CA Dinarello
  • J Endotoxin Res
  • 1999
1 Excerpt

Similar Papers

Loading similar papers…